Drug Trial Radar · NCT06721871
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
May 1, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Napo Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study that will evaluate the safety, tolerability and preliminary efficacy of multiple ascending doses of crofelemer, compared to placebo, using a randomized cross-over design within each dose level, when administered to participants with MVID receiving parenteral support (PS, defined as TPN with or without supplementary IV fluid requirements). Blinded study drug will be administered as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution. Assigned study drug will be reconstituted and administered orally (or enterally) three times daily (TID) as a concentrated liquid formulation in each of the three dose levels.
Conditions
- Microvillus Inclusion Disease
- Congenital Disorders
- Rare Diseases
Interventions
Crofelemer Powder for Oral SolutionDrug
Crofelemer Powder for Oral Solution
Placebo Powder for Oral SolutionDrug
Matching Placebo Powder for Oral Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 32 Weeks
- Changes in Physical ExaminationTime frame: 32 Weeks
- Changes in Laboratory ValuesTime frame: 32 Weeks
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Boston Children's Hospital
Boston, Massachusetts
UOS Gastroenterolgia e Riabilitazione nutrizionale Piazza Sant' Onofrio 4
Rome, Italy
Al Jalila Children's Hospital
Dubai, United Arab Emirates
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.